Who Buys Rivaroxaban from India — 497 Importers Behind a $52.6M Market

The 497 buyers of Rivaroxaban from India can be categorized into several segments:

1. Distributors: Entities like MYLAN IRELAND C/O ALLOGA RDC (Netherlands, $13.25M) and APOTEX INC (Canada, $1.27M) fall into this category. These companies purchase large volumes to supply pharmacies, hospitals, and other healthcare providers. Their buying behavior typically involves regular, high-volume orders to maintain a steady supply chain.

2. Contract Manufacturers: Companies such as PHARMADOX HEALTHCARE LTD (Malta, $3.93M) and GMP MANUFACTURING LTD (United Kingdom, $0.71M) are contract manufacturers. They procure Rivaroxaban to produce finished pharmaceutical products for other brands or companies. Their purchasing patterns are project-based, aligning with production schedules and client demands.

3. Government Procurement Agencies: Entities like HEALTH CARE AGENCY, SEYCHELLES (Seychelles, $0.92M) represent government procurement. These agencies acquire medications for public healthcare systems, often through tender-based processes. Their orders are typically large and periodic, corresponding with budget cycles and public health needs.

4. Re-exporters: Companies such as DEPO PACK SNC (Italy, $0.86M) may act as re-exporters, purchasing Rivaroxaban to supply other markets. Their buying behavior is influenced by global demand fluctuations and trade agreements.

5. Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, hospital groups and retail chains also procure Rivaroxaban directly for patient care. Their orders are generally smaller and more frequent, based on immediate patient needs and inventory management practices.

For the top five importing countries, the import regulations for Rivaroxaban are as follows:

The demand for Rivaroxaban in importing countries is driven by several factors:

1. Disease Prevalence: Rivaroxaban is primarily used to prevent and treat thromboembolic disorders. The prevalence of conditions such as atrial fibrillation and deep vein thrombosis has been increasing globally, contributing to higher demand for anticoagulant therapies.

2. Government Healthcare Programs: Many countries have implemented programs to improve access to essential medicines. For instance, the WHO's Model List of Essential Medicines includes anticoagulants like Rivaroxaban, encouraging member states to prioritize their procurement.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased public funding for essential medicines, including anticoagulants, thereby boosting demand.

4. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders, ensuring large-scale purchases and stable demand. The inclusion of Rivaroxaban in such tenders reflects its recognized therapeutic value.

With 497 buyers across 115 countries, the market for Rivaroxaban imported from India demonstrates significant global reach and sustained demand, presenting ongoing opportunities for exporters.

The 497 buyers of Rivaroxaban from India can be categorized into several segments:

1. Distributors: Entities like MYLAN IRELAND C/O ALLOGA RDC (Netherlands, $13.25M) and APOTEX INC (Canada, $1.27M) fall into this category. These companies purchase large volumes to supply pharmacies, hospitals, and other healthcare providers. Their buying behavior typically involves regular, high-volume orders to maintain a steady supply chain.

2. Contract Manufacturers: Companies such as PHARMADOX HEALTHCARE LTD (Malta, $3.93M) and GMP MANUFACTURING LTD (United Kingdom, $0.71M) are contract manufacturers. They procure Rivaroxaban to produce finished pharmaceutical products for other brands or companies. Their purchasing patterns are project-based, aligning with production schedules and client demands.

3. Government Procurement Agencies: Entities like HEALTH CARE AGENCY, SEYCHELLES (Seychelles, $0.92M) represent government procurement. These agencies acquire medications for public healthcare systems, often through tender-based processes. Their orders are typically large and periodic, corresponding with budget cycles and public health needs.

4. Re-exporters: Companies such as DEPO PACK SNC (Italy, $0.86M) may act as re-exporters, purchasing Rivaroxaban to supply other markets. Their buying behavior is influenced by global demand fluctuations and trade agreements.

5. Hospital Groups and Retail Chains: While not explicitly listed among the top buyers, hospital groups and retail chains also procure Rivaroxaban directly for patient care. Their orders are generally smaller and more frequent, based on immediate patient needs and inventory management practices.

For the top five importing countries, the import regulations for Rivaroxaban are as follows:

The demand for Rivaroxaban in importing countries is driven by several factors:

1. Disease Prevalence: Rivaroxaban is primarily used to prevent and treat thromboembolic disorders. The prevalence of conditions such as atrial fibrillation and deep vein thrombosis has been increasing globally, contributing to higher demand for anticoagulant therapies.

2. Government Healthcare Programs: Many countries have implemented programs to improve access to essential medicines. For instance, the WHO's Model List of Essential Medicines includes anticoagulants like Rivaroxaban, encouraging member states to prioritize their procurement.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased public funding for essential medicines, including anticoagulants, thereby boosting demand.

4. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders, ensuring large-scale purchases and stable demand. The inclusion of Rivaroxaban in such tenders reflects its recognized therapeutic value.

With 497 buyers across 115 countries, the market for Rivaroxaban imported from India demonstrates significant global reach and sustained demand, presenting ongoing opportunities for exporters.